Table 1 MED12 mutations, HMGA2 aberrations, and biallelic FH inactivation in uterine smooth muscle tumors
Smooth muscle tumor subtype | Total | MED12 mutation positive | HMGA2 overexpressing | FH deficient | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | % | P-value | 95% CI | N | % | P-value | 95% CI | N | % | P-value | 95% CI | ||
Conventional | 65 | 37 | 56.9 | 16 | 24.6 | 0 | 0 | ||||||
Histopathological UL variant | 94 | 17 | 18.1 | 5.2 × 10−7 | 2.76–13.14 | 13 | 13.8 | 0.10 | 0.83–5.01 | 8 | 8.5 | 0.02 | 0.00–0.81 |
Mitotically active | 25 | 9 | 36 | 0.10 | 0.83–6.93 | 1 | 4 | 0.03 | 1.07–341.56 | 0 | 0 | ||
Leiomyoma with bizarre nuclei | 18 | 3 | 16.7 | 3.0 × 10−3 | 1.61–38.18 | 0 | 0 | 0.02 | 1.24- ∞ | 6 | 33.3 | 4.9 × 10−5 | 0.00–0.19 |
Cellular | 25 | 4 | 16 | 7.3 × 10−4 | 1.98–30.31 | 8 | 32 | 0.60 | 0.23–2.23 | 1 | 4 | 0.28 | 0.00–15.00 |
Highly cellular | 37 | 3 | 8.1 | 6.0 × 10−7 | 3.98–81.73 | 4 | 10.8 | 0.12 | 0.77–11.96 | 1 | 2.7 | 0.36 | 0.00–22.20 |
Leiomyosarcoma | 51 | 11 | 21.6 | 1.4 × 10−4 | 1.96–12.16 | 3 | 5.9 | 0.01 | 1.35–29.40 | 2 | 3.9 | 0.19 | 0.00–4.16 |